Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07604233CT.gov Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | — | Not Yet Recruiting | — | — | — |
NCT06001788CT.gov Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT04678401CT.gov IS-free Treg HaploHCT | — | Recruiting | — | — | — |
NCT00133367CT.gov Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | M.D. Anderson Cancer Center | P2 | BB · 68 |
| Fludarabine | M.D. Anderson Cancer Center | P2/3 | BBB |
| Cyclophosphamide | Actinium Pharmaceuticals | P2/3 | BB |
| Cytarabine | M.D. Anderson Cancer Center | P3 | BB |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Melphalan | Dana-Farber Cancer Institute | P2 | B |
| Enasidenib | Tian Yi Zhang | P3 | B |
| Azacitidine | Jacqueline Garcia, MD | P3 | B |
+42 more in the Myeloid Leukemia cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →